Breaking News Instant updates and real-time market news.

UBER

Uber

$32.57

-0.53 (-1.60%)

, CTST

CannTrust

$1.67

-0.03 (-1.76%)

08:45
08/29/19
08/29
08:45
08/29/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Uber (UBER) 3.26% +0.65, CannTrust Holdings (CTST) 30.68% +0.29, Direxion Daily Gold Miners Bull 3X Shares (NUGT) 1.17% +0.29, Direxion Energy Bull 3x (ERX) 1.52% +0.23, iShares Turkey (TUR) 11.58% +0.22, Gold Fields (GFI) 0.56% +0.18, Tailored Brands (TLRD) 2.33% +0.14, SPDR S&P MIDCAP 400 (MDY) 0.39% +0.14, Health Insurance Innovations (HIIQ) 87.63% +0.13, and Booking Holdings (BKNG) 0.34% +0.09.

UBER

Uber

$32.57

-0.53 (-1.60%)

CTST

CannTrust

$1.67

-0.03 (-1.76%)

NUGT

Direxion Gold Miners Bull

$42.97

-0.64 (-1.47%)

TUR

iShares MSCI Turkey Index

$23.90

0.07 (0.29%)

GFI

Gold Fields

$6.00

-0.145 (-2.36%)

TLRD

Tailored Brands

$5.09

0.365 (7.73%)

MDY

SPDR S&P MidCap 400 ETF

$337.29

3.32 (0.99%)

HIIQ

Health Insurance Innovations

$18.05

0.21 (1.18%)

BKNG

Booking Holdings

$1,941.00

20.28 (1.06%)

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

  • 20

    Sep

  • 23

    Sep

UBER Uber
$32.57

-0.53 (-1.60%)

08/26/19
GUGG
08/26/19
UPGRADE
Target $60
GUGG
Buy
Guggenheim upgrades Lyft to Buy with fares rising, incentives falling
Guggenheim analyst Jake Fuller upgraded Lyft (LYFT) to Buy from Neutral with a $60 price target. The stock closed Friday at $49.11. Improving U.S. ride hail competitive dynamics and Lyft's "surprising leverage to that trend" should allow the company to reach EBITDA positive in 2021 versus prior expectations of 2023, Fuller tells investors in a research note. The key driver of the improving competitive backdrop is simple, says Fuller. Lyft and Uber Technologies (UBER) are now public, and Uber needs margin from U.S. ride hail to support its efforts internationally and in the "highly competitive" restaurant delivery business, argues Fuller. Fares are rising and incentives are falling, contends the analyst.
08/14/19
BERN
08/14/19
NO CHANGE
BERN
Tesla executive turnover notably high, 'not outlandish,' says Bernstein
Bernstein analyst A.M. Sacconaghi, Jr. performed a detailed benchmarking analysis of executive turnover at Tesla (TSLA) and at comparable companies that are young, fast growing, and largely Silicon Valley based, including Snap (SNAP), Uber (UBER), Lyft (LYFT), Airbnb, Netflix (NFLX), Facebook (FB) and Amazon (AMZN). His analysis indicates that Tesla's annualized executive turnover level has been 27%, "notably higher" than the cohort average of 15%. With that said, the analyst notes that it is "not outlandish," with Snap at 24% and Lyft at 23%, which is nearly as high.
08/09/19
LEHM
08/09/19
NO CHANGE
Target $50
LEHM
Overweight
Uber quarter positive 'under the scorched-earth rubble,' says Barclays
For those investors looking "under the scorched-earth rubble," there are actually some positive things going on at Uber Technologies, Barclays analyst Ross Sandler tells investors in a post-earnings research note. Stripping out one-time initial public offering-related driver payments, core Rides adjusted net revenue accelerated to 20% year-over-year, says the analyst. He thinks "risk-seeking, opportunistic" investors should take advantage of any weakness into Uber's lock-up expiration. Sandler keeps a Buy rating on Uber with a $50 price target.
08/09/19
COWN
08/09/19
NO CHANGE
Target $60
COWN
Outperform
Uber price target raised to $60 from $58 at Cowen
Cowen analyst John Blackledge raised his price target on Uber to $60 from $58 following strong Q2 results fueled by rising take rates at both Rides and Eats. The analyst said guidance was positive on topline and EBITDA. Blackledge reiterated his Outperform rating on Uber shares.
CTST CannTrust
$1.67

-0.03 (-1.76%)

07/09/19
ROTH
07/09/19
DOWNGRADE
Target $4
ROTH
Neutral
CannTrust downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Fortune downgraded CannTrust to Neutral from Buy, noting that the company has taken a "huge credibility hit" from the issued Health Canada non-compliance rating audit report, in which Health Canada has placed a hold on about 5,200 kg of dried cannabis. To be determined is Health Canada's enforcement response to what he deems a "flagrant lack of compliance" surrounding cultivating cannabis in five unlicensed rooms over a five-month timeframe. The analyst believes the operations misstep will have material impact to financials. Fortune also lowered his price target on the shares to $4 from $8.50.
07/08/19
BOFA
07/08/19
DOWNGRADE
Target $3.5
BOFA
Underperform
BofA double downgrades CannTrust to Underperform after Health Canada probe
BofA Merrill Lynch analyst Christopher Carey downgraded CannTrust two notches, to Underperform from Buy, and halved his price target on the shares $3.50 from $7 after the company announced that an audit from Health Canada found it had cultivated cannabis in rooms not yet licensed to do so and put a freeze on some of the company's inventory. Even following this morning's slide he expects the stock to remain weak due to uncertainty on the impact of the probe on CannTrust's financials as well as due to likely diminished investor confidence, said Carey. In morning trading in New York, CannTrust shares are down 92c, or 19%, to $4.02.
07/12/19
07/12/19
DOWNGRADE

CannTrust downgraded to Sell from Neutral at Eight Capital
Eight Capital analyst Graeme Kreindler downgraded CannTrust Holdings to Sell from Neutral and cut his price target for the shares to C$4 from C$6. The analyst downgraded the shares to Neutral on July 8.
07/08/19
07/08/19
DOWNGRADE

CannTrust downgraded to Neutral from Buy at Eight Capital
Eight Capital analyst Graeme Kreindler earlier today downgraded CannTrust Holdings to Neutral from Buy and lowered his price target for the shares to C$6 from C$11.
NUGT Direxion Gold Miners Bull
$42.97

-0.64 (-1.47%)

TUR iShares MSCI Turkey Index
$23.90

0.07 (0.29%)

GFI Gold Fields
$6.00

-0.145 (-2.36%)

04/01/19
RBCM
04/01/19
NO CHANGE
RBCM
Outperform
Gold Fields price target raised to ZAR6,300 from ZAR5,800 at RBC Capital
RBC Capital analyst James Bell maintained an Outperform rating on Gold Fields and raised his price target to ZAR6,300 from ZAR5,800, telling investors in a research note that he thinks the company is set for a "strong" 2019. With a free cash flow inflection now underway and problem asset South Deep de-emphasized, Bell sees scope for a re-rating ahead of peers.
06/26/19
RBCM
06/26/19
DOWNGRADE
RBCM
Sector Perform
Gold Fields downgraded to Sector Perform from Outperform at RBC Capital
04/25/19
BMOC
04/25/19
UPGRADE
Target $5
BMOC
Outperform
Gold Fields upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Andrew Kaip upgraded Gold Fields to Outperform and raised his price target to $5 from $4 after its better than expected Q1 production that "positions the company at the top end of 2019 guidance." The anajyst warns that South Africa risks remain, but with "progress at South Deep above expectations", Kaip believes the output sets the "stage for further gains through 2019." Kaip adds that Gold Fields' international portfolio is expected to reach a cash flow inflection in the second half of 2019.
06/26/19
RBCM
06/26/19
DOWNGRADE
RBCM
Sector Perform
Gold Fields running 'well ahead' of peers in last 3 months, says RBC Capital
RBC Capital analyst James Bell downgraded Gold Fields (GFI) to Sector Perform from Outperform, telling investors in a research note that while the company's two-year reinvestment plan is paying off, the stock has run "well ahead" of its peers in the last three months. The analyst recommends a rotation into peer AngloGold (AU), which he upgraded to Outperform. The Gold Fields story is delivering against expectations, Bell says, but there are less catalysts from here than AngloGold, Bell says.
TLRD Tailored Brands
$5.09

0.365 (7.73%)

12/18/18
12/18/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Logitech (LOGI) initiated with an Outperform at Wedbush. 2. Alnylam (ALNY) initiated with a Buy at Guggenheim, while BioMarin (BMRN) was initiated with a Neutral. 3. Tailored Brands (TLRD) initiated with a Buy at B. Riley FBR. 4. Adecogro (AGRO) initiated with a Neutral at Citi. 5. Shopify (SHOP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/19
RILY
06/13/19
NO CHANGE
Target $7
RILY
Neutral
Tailored Brands price target lowered to $7 from $10 at B. Riley FBR
B. Riley FBR analyst Susan Anderson lowered her price target for Tailored Brands to $7 from $10 saying "challenges remain" after the company's Q2 guidance missed expectations. The analyst believes Tailored Brands is "on the right track" with its changes to the product assortment, cost savings program, and omni-channel initiatives, but she remains on the sidelines pending stabilization in same-store-sales and greater visibility into its long-term performance. Anderson keeps a Neutral rating on the shares.
03/14/19
RILY
03/14/19
DOWNGRADE
Target $11
RILY
Neutral
Tailored Brands downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Susan Anderson downgraded Tailored Brands to Neutral from Buy and cut her price target for the shares to $11 from $20. The analyst sees a lack of near-term visibility into when same-store-sales will stabilize.
03/14/19
JEFF
03/14/19
NO CHANGE
Target $19
JEFF
Buy
Jefferies cuts Tailored Brands target to $19, admits to making 'terrible' call
In a research note titled "How Could We Be So Wrong?" Jefferies analyst Randal Konik lowered his price target for Tailored Brands to $19 from $24. "Let's begin with our call has been terrible here," Konik writes. Tailored's business is "challenged and is getting worse," visibility seems very low and management seems to be questioning the execution of some of its strategies, Konik says following the company's Q4 results. He believes the stock will remain in the "penalty box" until the business can show some stabilization. However, with a "cheap" valuation and "less significant downside potential" from current levels, Konik keeps a Buy rating on Tailored Brands.
MDY SPDR S&P MidCap 400 ETF
$337.29

3.32 (0.99%)

HIIQ Health Insurance Innovations
$18.05

0.21 (1.18%)

08/06/19
CHLM
08/06/19
NO CHANGE
Target $50
CHLM
Buy
Health Insurance Innovations price target cut to $50 from $65 at Craig-Hallum
Craig-Hallum analyst George Sutton lowered his price target for Health Insurance Innovations to $50 from $65 following quarterly results and as he expects the stock to remain volatile going forward. The analyst reiterates a Buy rating on the shares given an attractive risk-reward scenario.
08/16/19
PIPR
08/16/19
NO CHANGE
Target $87
PIPR
Overweight
Teladoc short report selloff brings buying opportunity, says Piper Jaffray
Shares of Teladoc Health (TDOC) fell yesterday after a short report raised questions about the company's relationship with Health Insurance Innovations (HIIQ), Piper Jaffray analyst Sean Wieland tells investors in a research note. After speaking with Teladoc's CFO, the analyst believes the "drama is unwarranted," and he encourages investors to take advantage of "another buying opportunity." The CFO told Wieland that Health Insurance is a client of Teladoc under the "visits included" model, which means neither Health Insurance nor the member pay a fee each time the service is used. According to Teladoc, less than 1% of revenue and EBITDA is tied to Health Insurance Innovations, Wieland tells investors in a research note. He believes the short report is "flawed because it relies on inaccurate assumptions and slippery-slope logic." Wieland reiterates an Overweight rating on Teladoc with an $87 price target. The stock closed yesterday down 7.5%, or $4.56, to $56.94.
08/13/19
CANT
08/13/19
NO CHANGE
Target $80
CANT
Overweight
Health Insurance cash flow not major concern, says Cantor Fitzgerald
After reviewing Health Insurance Innovations' cash flow during the first half of 2019, Cantor Fitzgerald analyst Steven Halper is not that concerned about the company's use of cash. Excluding different items, the company generated free cash flow over the trailing 12 months, which makes the reported negative cash flow not a major concern, Halper tells investors in a research note. Looking ahead, it is entirely possible that Health Insurance will continue to use cash as it begins to build up its Medicare business, adds the analyst. However, he remains optimistic about its Medicare initiative, which he believes should enhance its valuation over time. Halper reiterates an Overweight rating on Health Insurance Innovations with an $80 price target.
08/06/19
LSCM
08/06/19
NO CHANGE
Target $40
LSCM
Buy
Health Insurance Innovations price target lowered to $40 from $50 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Health Insurance Innovations to $40 from $50 and maintains a Buy rating on the shares following the company's Q2 results. Health Insurance is a "show me story" in transition as it aggressively moves away from short-duration plans and ramps up investments in other offerings, Argento tells investors in a research note.
BKNG Booking Holdings
$1,941.00

20.28 (1.06%)

08/08/19
DBAB
08/08/19
NO CHANGE
Target $2275
DBAB
Buy
Booking Holdings price target raised to $2,275 from $2,175 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Booking Holdings to $2,275 from $2,175 saying he come out of the copay's Q2 results "feeling marginally better" about the underlying growth at Booking.com. As investments in payments and brand normalize, the company should see faster EBITDA growth, Walmsley tells investors in a post-earnings research note. He keeps a Buy rating on the shares.
08/08/19
WEDB
08/08/19
NO CHANGE
Target $1950
WEDB
Neutral
Booking Holdings price target raised to $1,950 from $1,850 at Wedbush
Wedbush analyst James Hardiman raised his price target for Booking Holdings to $1.950 from $1,850 saying that Q2 was "a welcome surprise" following a Q4 print and guide that "spooked investors" with regards to the European outlook and even a Q1 print that did little to alleviate these concerns. The analyst notes that the company seems to be back to its standard of comfortably exceeding quarterly expectations and providing a quarterly guidance that, while certainly not blowing away Street estimates, does encompass the consensus. Hardiman reiterates a Neutral rating on the shares.
08/08/19
LEHM
08/08/19
NO CHANGE
Target $2140
LEHM
Overweight
Booking Holdings price target raised to $2,140 from $2,080 at Barclays
Barclays analyst Deepak Mathivanan raised his price target for Booking Holdings to $2,140 from $2,080 saying the company's fundamentals are "improving steadily." The company is achieving "good progress" on various long-term initiatives, including new customer acquisition efforts, merchandising programs, and payments, says the analyst. He reiterates an Overweight rating on Booking Holdings following its Q2 results.
08/08/19
COWN
08/08/19
NO CHANGE
Target $2300
COWN
Outperform
Booking Holdings price target raised to $2,300 from $2,160 at Cowen
Cowen analyst Kevin Kopelman raised his price target on Booking Holdings to $2,300 from $2,160 following solid Q2 results. The analyst noted they slightly exceeded his Street-high estimates for nights and EBITDA. He expects to moderate as comps toughen in the second half and for macro uncertainty to persist. Kopelman raised his price target and reiterated his Outperform rating on Booking Holdings shares.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.